A familial Alzheimer's genetic panel sequences three genes — PSEN1, PSEN2, and APP — to find the mutation behind early-onset, autosomal-dominant Alzheimer's disease, the inherited form that runs in families and typically causes symptoms before age 65. When someone with new memory symptoms also has a family history suggesting this pattern, the panel identifies a causative variant in roughly 60-80% of cases, according to ARUP Consult. That leaves 20-40% of symptomatic, family-history-positive cases unexplained by the panel, and the test carries real technical limits, insurance consequences, and emotional stakes that are worth understanding before ordering it. The sections below cover what the panel actually measures, what it can miss, how to prepare for it responsibly, and what a result means for both the person tested and their relatives.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the Panel Tests and How Reliable Is It
- What the Test Can Miss
- Preparing Before the Test — Family History and Counseling
- What a Result Can Mean for Insurance and Family Members
- If Alzheimer's Drug Treatment Becomes a Question
- Frequently Asked Questions
What the Panel Tests and How Reliable Is It
The panel targets three genes known to cause autosomal-dominant Alzheimer's disease, meaning a single copy of a mutated gene, inherited from one parent, is enough to cause the disease. Among cases where a variant is found, PSEN1 accounts for 20-70%, APP for 10-15%, and PSEN2 for about 5%, per ARUP Consult. Which gene is involved changes how much a positive result tells you.
ARUP Consult notes that PSEN1 and APP variants show near-complete penetrance, meaning almost everyone who carries one eventually develops the disease, while PSEN2 variants show reduced penetrance — carrying one does not make the outcome as certain. A PSEN2 finding is real information, but it answers a different question than a PSEN1 or APP finding does. The 20-40% of cases where no variant turns up are not necessarily free of inherited risk. They may reflect a cause the panel's method cannot see, a family history that looks autosomal-dominant but isn't, or a gene not yet linked to the disease.
What the Test Can Miss
The panel's sequencing method reads coding regions and the boundaries between introns and exons — the parts of the gene directly translated into protein and the splice sites next to them. ARUP Consult reports that this method does not catch deep intronic or regulatory-region changes, nor does it catch larger structural changes such as deletions, duplications, or insertions.
Those larger structural variants require a separate copy-number analysis, which is not automatically bundled into the standard sequencing panel. Anyone with a strong family history and a negative sequencing result should ask whether copy-number testing was included, since a true familial mutation can exist in a form the first test was never designed to detect.
Preparing Before the Test — Family History and Counseling
A result is only as interpretable as the family history behind it. The 2011 joint practice guideline from the American College of Medical Genetics and the National Society of Genetic Counselors calls for building a three-generation family history before testing, because early deaths from other causes or an undisclosed non-biological parent can make a family look free of the disease when it isn't. That same guideline states the test should be ordered only alongside genetic counseling from someone with expertise in the area — not as a standalone lab order.
A counselor can map the family history accurately, explain what a given gene's result does and does not mean, and walk through the consequences before blood is drawn rather than after. This caution extends beyond people who already have symptoms. The Alzheimer's Association's Genetic Testing Statement advises against testing healthy, asymptomatic individuals for Alzheimer's risk outside of counseling, research, or a clinical trial, since routine testing without that structure has limited clinical value.
What a Result Can Mean for Insurance and Family Members
A genetic test result has legal reach beyond the clinic. The Genetic Information Nondiscrimination Act of 2008 stops health insurers and employers from using genetic results against someone, but it does not cover life, disability, or long-term-care insurance — a positive result for a familial Alzheimer's variant can legally affect eligibility or pricing for those policies.
The decision to test also carries weight for at-risk relatives who haven't yet shown symptoms, since a confirmed mutation in the family changes what their own result would mean. A study of Italy's IT-DIAfN predictive-testing protocol, published in Alzheimer's Research & Therapy, found that of 11 at-risk relatives who initially requested testing, 8 withdrew before blood was even drawn, most after fully grappling with what an unfavorable result would mean. No one who completed testing in that group had a catastrophic reaction — but the high withdrawal rate shows how much weight people give the decision once they sit with it.
If Alzheimer's Drug Treatment Becomes a Question
A different gene, APOE, becomes relevant once treatment is on the table rather than diagnosis. APOE-ε4 is the strongest known genetic risk factor for late-onset Alzheimer's, and the Alzheimer's Association and Quest Diagnostics note that what a positive result means for risk is not the same across every racial and ethnic group, which is another reason a genetic counselor should interpret it rather than a lab report alone. APOE-ε4 status now directly affects access to two approved Alzheimer's drugs.
The FDA's label for donanemab (Kisunla) carries a boxed warning for ARIA, a type of brain swelling or bleeding, and states that APOE-ε4 genotyping should be done before starting treatment because ε4 homozygotes face substantially higher ARIA rates than heterozygotes or noncarriers. The UK's medicines regulator went further with lecanemab, concluding its risk-benefit balance is favorable for APOE4 noncarriers and heterozygotes but not for homozygotes, and recommending APOE4 testing before treatment starts. Anyone whose memory symptoms lead toward one of these drugs should expect APOE testing to be part of that workup, separate from the PSEN1/PSEN2/APP panel used for suspected familial disease.
Frequently Asked Questions
Is the familial Alzheimer's panel the same as APOE testing?
No. The panel sequences PSEN1, PSEN2, and APP for autosomal-dominant, typically early-onset disease, while APOE-ε4 is a separate risk-factor gene relevant to late-onset disease and to eligibility for drugs like donanemab and lecanemab.
Does a negative panel result rule out a genetic cause?
Not entirely. Standard sequencing misses deep intronic and regulatory variants and structural changes like deletions or duplications, which need separate copy-number testing, per ARUP Consult.
Can a positive result affect insurance?
It can affect life, disability, and long-term-care insurance, since federal nondiscrimination law only covers health insurance and employment.
